A part of MilliporeSigma

ABN454 | Anti-Tau (T22), oligomeric Antibody

100 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited AvailabilityLimited Availability
Limited Quantities Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers


      Contact Customer Service

      Click To Print This Page


      Replacement Information

      Key Specifications Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H DB, ELISA, IF, IHC, IP, NEUT, WB Rb Serum Polyclonal Antibody
      Catalogue NumberABN454
      DescriptionAnti-Tau (T22), oligomeric Antibody
      Alternate Names
      • Microtubule-associated protein tau oligomer
      • Tau oligomer
      • PHF-tau oligomer
      • Paired helical filament-tau oligomer
      • Neurofibrillary tangle protein oligomer
      Background InformationMicrotubule-associated protein tau (UniProt P10636; also known as Neurofibrillary tangle protein, Paired helical filament-tau, PHF-tau) is encoded by the MAPT (also known as TAU, MAPT1, MTBTL) gene (Gene ID 4137) in human. In Alzheimer's disease (AD) pathology, accumulation of the microtubule-associated protein tau takes place primarily in the neurons. Tau accumulates in both the somatodendritic and axonal domains of neurons. Tau also accumulates in the soma as neurofibrillary tangles (NFTs). Cell death and synaptic lesions occur independently of NFT formation, and research indicates that NFT formation alone is insufficient for neurodegeneration, suggesting that soluble tau aggregates may be the more toxic and pathologically significant tau species. Tau oligomers are neurotoxic when applied extracellularly to cultured neuronal cells, and tau oligomers (but not fibrils) induce neurodegeneration and synaptic and mitochondrial dysfunction in vivo. Moreove, researchers are able to use tau oligomers as a reliable biomarker to differentiate AD brains from age-matched non-AD brains.
      Product Information
      PresentationRabbit polyclonal serum containing 0.05% sodium azide.
      ApplicationThis Anti-Tau (T22) antibody, oligomeric is validated for use in Dot Blot, ELISA, Immunofluorescence, Immunohistochemistry, Immunoprecipitation, Neutralization, and Western blotting.
      Key Applications
      • Dot Blot
      • ELISA
      • Immunofluorescence
      • Immunohistochemistry
      • Immunoprecipitation
      • Neutralizing
      • Western Blotting
      Application NotesDot Blot (Specificity) Analysis: A 1:1,000 dilution from a representative lot detected oligomeric tau, but not monomeric tau or tau fibrils.

      Immunohistochemistry Analysis: A 1:245-1,000 dilution from a representative lot detected tau oligomers in frontal cortices from Alzheimer's Diseased (AD) and Lewy Body Diseased (LBD) patients (Courtesy of Prof. Rakez Kayed, University of Texas, Galveston).

      Immunofluorescence Analysis: A representative lot detected oligomeric tau in chronic traumatic encephalopathy (CTE) brain tissue sections, while little or no tau oligomer immunoreactivity was seen in non-CTE human brain sections. The tau oligomer immunoreactivity colocalized with that of tau pThr231 with a cis conformation, but not tau pThr231 with a trans conformation, between pThr231 and Pro232 (Kondo, A., et al. (2015). Nature. 523(7561):431-436).

      Immunofluorescence Analysis: A representative lot detected oligomeric tau immunoreactivity in paraffin-embedded frontal cortex sections from Alzheimer's diseased (AD) brains (Lasagna-Reeves, C. A., et al. (2012). FASEB J. 26(5):1946-1959).

      Western Blotting Analysis: Representative lots detected oligomeric tau, but not monomeric tau, or any other oligomeric and fibrillar proteins (Wu J.W., et al. (2013). J. Biol. Chem. 288(3):1856-1870; Lasagna-Reeves, C. A., et al. (2012). FASEB J. 26(5):1946-1959).

      Dot Blot Analysis: A representative lot detected tau oligomers, but not tau monomer or paired helical filaments (PHFs) (Lasagna-Reeves, C. A., et al. (2012). FASEB J. 26(5):1946-1959).

      ELISA Analysis: Representative lots detected vitro formed tau oligomers as well as tau oligomers in PBS-soluble brain extracts from progressive supranuclear palsy (PSP) patients (Lasagna-Reeves, C.A., et al. (2012). Sci. Rep. 2:700; Lasagna-Reeves, C. A., et al. (2012). FASEB J. 26(5):1946-1959).

      ELISA Analysis: A representative lot showed selective reactivity toward oligomeric tau, while exhibiting greatly reduced immunoreactivity toward tau fibrils, and no reactivity toward monomeric tau, or other protein oligomers or fibrils (e.g., Aβ, α-synuclein, or islet amyloid polypeptide) (Lasagna-Reeves, C. A., et al. (2012). FASEB J. 26(5):1946-1959).

      Immunoprecipitation Analysis: Representative lots immunoprecipitated oligomeric tau from Alzheimer's Diseased (AD), but not non-AD brains (Lasagna-Reeves, C.A., et al. (2012). Sci. Rep. 2:700; Lasagna-Reeves, C. A., et al. (2012). FASEB J. 26(5):1946-1959).

      Neutralizing Analysis: Representative lots neutralized oligomeric tau toxicity to SH-SY5Y human neuroblastoma cells (Lasagna-Reeves, C.A., et al. (2012). Sci. Rep. 2:700; Lasagna-Reeves, C. A., et al. (2012). FASEB J. 26(5):1946-1959).

      Immunohistochemistry Analysis: A representative lot detected oligomeric tau immunoreactivity in paraffin-embedded brain sections from progressive supranuclear palsy (PSP) patients (Lasagna-Reeves, C. A., et al. (2012). FASEB J. 26(5):1946-1959).
      Biological Information
      ImmunogenRecombinant human Tau-441 (Tau-F, Tau-4, 2N4R isoform) oligomers (Lasagna-Reeves, C. A., et al. (2012). FASEB J. 26(5):1946-1959).
      SpecificityT22 specifically recognizes and neutralizes oligomeric tau, T22 does not show any significant reactivity toward monomeric tau, tau fibrils, Aβ oligomers, Aβ fibrils, α-synuclein oligomers, or α-synuclein fibrils (Lasagna-Reeves, C. A., et al. (2012). FASEB J. 26(5):1946-1959).
      Species Reactivity
      • Human
      Species Reactivity NoteHuman.
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Gene Symbol
      • MAPT
      • TAU
      • MTBT1
      • MAPTL
      Purification MethodUnpurified
      UniProt Number
      Molecular WeightVariable depending on the size(s) of the oligomer(s).
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceEvaluated by Western Blotting in human brain tissue lysates.

      Western Blotting Analysis: A 1:1,000 dilution of this antibody detected tau oligomers in Alzheimer's diseased (AD), but not non-AD, human brain tissue lysate.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at -20°C from date of receipt.
      Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information




      Safety Data Sheet (SDS) 

      Certificates of Analysis

      TitleLot Number
      Anti-Tau (T22), Oligomeric -2702136 2702136
      Anti-Tau (T22), Oligomeric -2730017 2730017
      Anti-Tau (T22), Oligomeric -2776621 2776621
      Anti-Tau (T22), Oligomeric -2798560 2798560
      Anti-Tau (T22), oligomeric 2485426
      Anti-Tau (T22), oligomeric - 2428895 2428895
      Anti-Tau (T22), oligomeric - 2442562 2442562
      Anti-Tau (T22), oligomeric - 2459112 2459112
      Anti-Tau (T22), oligomeric - Q2384858 Q2384858
      Anti-Tau (T22), oligomeric - 2562019 2562019
      Anti-Tau (T22), oligomeric -2515443 2515443
      Anti-Tau (T22), oligomeric -2523889 2523889
      Anti-Tau (T22), oligomeric -2594430 2594430
      Anti-Tau (T22), oligomeric -2613130 2613130
      Anti-Tau (T22), oligomeric -2642217 2642217
      Anti-Tau (T22), oligomeric -2668509 2668509


      Reference overviewApplicationSpeciesPub Med ID
      Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons.
      Wu, JW; Herman, M; Liu, L; Simoes, S; Acker, CM; Figueroa, H; Steinberg, JI; Margittai, M; Kayed, R; Zurzolo, C; Di Paolo, G; Duff, KE
      The Journal of biological chemistry 288 1856-70 2013

      Show Abstract
      Immunoblotting (Western)Rat23188818 23188818
      Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: possible link between traumatic brain injury and sporadic tauopathies.
      Hawkins, BE; Krishnamurthy, S; Castillo-Carranza, DL; Sengupta, U; Prough, DS; Jackson, GR; DeWitt, DS; Kayed, R
      The Journal of biological chemistry 288 17042-50 2013

      Show Abstract
      Immunoblotting (Western)Human23632019 23632019
      Accelerated neurodegeneration through chaperone-mediated oligomerization of tau.
      Blair, LJ; Nordhues, BA; Hill, SE; Scaglione, KM; O'Leary, JC; Fontaine, SN; Breydo, L; Zhang, B; Li, P; Wang, L; Cotman, C; Paulson, HL; Muschol, M; Uversky, VN; Klengel, T; Binder, EB; Kayed, R; Golde, TE; Berchtold, N; Dickey, CA
      The Journal of clinical investigation 123 4158-69 2013

      Show Abstract
      Immunoblotting (Western)Rat23999428 23999428
      Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.
      Lasagna-Reeves, CA; Castillo-Carranza, DL; Sengupta, U; Sarmiento, J; Troncoso, J; Jackson, GR; Kayed, R
      FASEB journal : official publication of the Federation of American Societies for Experimental Biology 26 1946-59 2012

      Show Abstract
      ImmunohistochemistryMouse22253473 22253473
      Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau.
      Lasagna-Reeves, CA; Castillo-Carranza, DL; Sengupta, U; Guerrero-Munoz, MJ; Kiritoshi, T; Neugebauer, V; Jackson, GR; Kayed, R
      Scientific reports 2 700 2012

      Show Abstract
      Rat23050084 23050084